Open AccessP915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
Author(s) -
Kastritis E.,
Minnema M. C.,
Dimopoulos M. A.,
Merlini G.,
Theodorakakou F.,
Fotiou D.,
Huart A.,
Belhadj K.,
Gkolfinopoulos S.,
Manousou K.,
Sonneveld P.,
Palladini G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846528.55550.9c
Subject(s) - medicine , tolerability , al amyloidosis , daratumumab , clinical endpoint , bortezomib , amyloidosis , multiple myeloma , gastroenterology , surgery , adverse effect , oncology , clinical trial , antibody , immunology , immunoglobulin light chain